Ann Lab Med 2017; 37(2): 159-161
Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations
Yoko Kubuki, M.D.1,2, Kotaro Shide, M.D.2, Takuro Kameda, M.D.2, Takumi Yamaji, M.D.2, Masaaki Sekine, M.D.2, Ayako Kamiunten, M.D.2, Keiichi Akizuki, M.D.2, Haruko Shimoda, M.D.1,2, Yuki Tahira, M.D.2, Kenichi Nakamura, M.D.2, Hiroo Abe, M.D.2, Tadashi Miike, M.D.2, Hisayoshi Iwakiri, M.D.2, Yoshihiro Tahara, M.D.2,3, Mitsue Sueta, M.D.2, Kanna Hashimoto, M.D.2, Shojiro Yamamoto, M.D.2, Satoru Hasuike, M.D.2, Tomonori Hidaka, M.D.2,3, Kenji Nagata, M.D.2,4, Akira Kitanaka, M.D.2, and Kazuya Shimoda, M.D.2
Department of Transfusion and Cell Therapy1, University of Miyazaki Hospital; Department of Gastroenterology and Hematology2, Faculty of Medicine, University of Miyazaki; Oncology Unit3, University of Miyazaki Hospital; Liver Disease Center4, University of Miyazaki Hospital, Miyazaki, Japan
Correspondence to: Kazuya Shimoda
Department of Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan
Tel: +81-985-85-9121, Fax: +81-985-85-5194 E-mail:
Received: June 20, 2016; Revised: August 9, 2016; Accepted: December 1, 2016; Published online: March 1, 2017.
© The Korean Society for Laboratory Medicine. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

This Article



Indexed/Covered by